Puma Biotechnology, Inc. (PBYI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.55+1.49%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PBYI
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 231.2 | 228.4 | 230.5 | 235.6 | 228.0 | 253.2 | 225.1 | 272.3 | 251.0 | 27.7 | — | — | — | — | — | — |
| Total Revenues | — | — | — | — | — | — | — | — | — | 27.7 | — | — | — | — | — | — |
| Cost of Revenues | 58.2 | 58.2 | 64.4 | 62.7 | 55.1 | 63.7 | 39.4 | — | 34.6 | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 71.2 | 70.8 | 80.2 | 89.9 | 90.0 | 116.3 | 118.5 | 141.6 | 146.2 | 106.7 | — | — | — | — | — | — |
| R&D Expenses | — | — | — | — | — | 71.9 | 97.7 | 132.9 | 164.9 | 207.8 | 222.8 | 208.5 | 122.9 | 45.0 | 49.6 | 0.8 |
| Operating Income | 30.4 | 37.3 | 31.0 | 32.6 | 23.7 | 1.3 | (30.4) | (39.0) | (94.7) | (292.4) | (276.6) | (240.3) | (142.3) | (54.8) | (74.5) | (10.2) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 6.6 | 12.5 | 13.3 | 11.6 | 12.8 | 14.0 | 15.0 | 11.0 | 0.7 | — | — | — | — | — | — |
| Interest & Investment Income | 3.9 | 4.1 | 4.7 | 2.6 | 0.8 | 0.2 | 0.5 | 2.8 | 1.8 | 1.3 | 1.0 | 1.0 | 0.3 | 0.2 | 0.1 | 0.0 |
| Net Interest Expenses | — | — | — | 10.7 | 10.8 | 12.6 | 13.6 | 12.2 | 9.2 | (0.5) | — | — | — | — | — | — |
| Other Non-Operating Income / Expenses | 0.7 | (1.5) | (6.9) | (10.0) | (23.3) | (30.1) | (29.4) | (36.5) | (18.9) | 0.4 | 0.6 | 1.0 | 0.3 | 0.2 | 0.1 | (0.1) |
| Asset Writedown | — | — | — | 0.6 | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 31.2 | 35.8 | 24.1 | 22.7 | 0.5 | (28.8) | (59.8) | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | 4.7 | (6.2) | 1.1 | 0.5 | 0.3 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 26.7 | 31.1 | 30.3 | 21.6 | 0.0 | 29.1 | (60.0) | (75.6) | (113.6) | (292.0) | (276.0) | (239.3) | (142.0) | (54.7) | (74.4) | (10.2) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.52 | 0.62 | 0.62 | 0.46 | 0.00 | (0.72) | (1.52) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 0.51 | 0.61 | 0.62 | 0.45 | 0.00 | (0.72) | (1.52) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 4.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 50.9 | 50.0 | 48.6 | 47.1 | 44.7 | 40.6 | 39.6 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 52.6 | 50.7 | 49.1 | 47.6 | 44.9 | 40.6 | 39.6 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 48.2 | 42.5 | 44.2 | 33.6 | 12.6 | (20.4) | (31.0) | (87.3) | (289.6) | (275.4) | (239.5) | (141.6) | (54.4) | (74.2) | (10.1) |
| EBIT | 30.4 | 37.3 | 31.0 | 32.6 | 23.7 | 1.3 | (30.4) | (39.0) | (94.7) | (292.4) | (276.6) | (240.3) | (142.3) | (54.8) | (74.5) | (10.2) |
| Effective Tax Rate | — | — | — | 4.8% | 99.6% | -1.1% | -0.3% | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.